284 related articles for article (PubMed ID: 26711563)
1. Intrathecal-specific glutamic acid decarboxylase antibodies at low titers in autoimmune neurological disorders.
Sunwoo JS; Chu K; Byun JI; Moon J; Lim JA; Kim TJ; Lee ST; Jung KH; Park KI; Jeon D; Jung KY; Kim M; Lee SK
J Neuroimmunol; 2016 Jan; 290():15-21. PubMed ID: 26711563
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
3. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies.
Malter MP; Frisch C; Zeitler H; Surges R; Urbach H; Helmstaedter C; Elger CE; Bien CG
Seizure; 2015 Aug; 30():57-63. PubMed ID: 26216686
[TBL] [Abstract][Full Text] [Related]
4. The neurological syndromes associated with glutamic acid decarboxylase antibodies.
Baizabal-Carvallo JF
J Autoimmun; 2019 Jul; 101():35-47. PubMed ID: 31000408
[TBL] [Abstract][Full Text] [Related]
5. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity.
Rakocevic G; Raju R; Dalakas MC
Arch Neurol; 2004 Jun; 61(6):902-4. PubMed ID: 15210528
[TBL] [Abstract][Full Text] [Related]
6. Glutamic acid decarboxylase antibody-associated neurological syndromes: Clinical and antibody characteristics and therapy response.
Madlener M; Strippel C; Thaler FS; Doppler K; Wandinger KP; Lewerenz J; Ringelstein M; Roessling R; Menge T; Wickel J; Kellingshaus C; Mues S; Kraft A; Linsa A; Tauber SC; Berg FT; Gerner ST; Paliantonis A; Finke A; Priller J; Schirotzek I; Süße M; Sühs KW; Urbanek C; Senel M; Sommer C; Kuempfel T; Pruess H; Fink GR; Leypoldt F; Melzer N; Malter MP;
J Neurol Sci; 2023 Feb; 445():120540. PubMed ID: 36608627
[TBL] [Abstract][Full Text] [Related]
7. Serum glutamate decarboxylase antibodies and neurological disorders: when to suspect their association?
Lacruz Ballester L; Fernandez-Fournier M; Puertas Muñoz I; Rodriguez Fraga O; Lastras Fernandez-Escandon C; Rodriguez de Rivera Garrido FJ; Alba Suarez EM; Tallon Barranco A
Neurol Sci; 2022 Jan; 43(1):633-641. PubMed ID: 33914193
[TBL] [Abstract][Full Text] [Related]
8. GAD antibodies in neurological disorders - insights and challenges.
Graus F; Saiz A; Dalmau J
Nat Rev Neurol; 2020 Jul; 16(7):353-365. PubMed ID: 32457440
[TBL] [Abstract][Full Text] [Related]
9. Neurologic disorders associated with anti-glutamic acid decarboxylase antibodies: A comparison of anti-GAD antibody titers and time-dependent changes between neurologic disease and type I diabetes mellitus.
Nakajima H; Nakamura Y; Inaba Y; Tsutsumi C; Unoda K; Hosokawa T; Kimura F; Hanafusa T; Date M; Kitaoka H
J Neuroimmunol; 2018 Apr; 317():84-89. PubMed ID: 29338930
[TBL] [Abstract][Full Text] [Related]
10. Neurological Syndromes Associated with Anti-GAD Antibodies.
Dade M; Berzero G; Izquierdo C; Giry M; Benazra M; Delattre JY; Psimaras D; Alentorn A
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456344
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
[TBL] [Abstract][Full Text] [Related]
12. Immunology of stiff person syndrome and other GAD-associated neurological disorders.
Alexopoulos H; Dalakas MC
Expert Rev Clin Immunol; 2013 Nov; 9(11):1043-53. PubMed ID: 24168411
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome.
Dinkel K; Meinck HM; Jury KM; Karges W; Richter W
Ann Neurol; 1998 Aug; 44(2):194-201. PubMed ID: 9708541
[TBL] [Abstract][Full Text] [Related]
14. Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome.
Chang T; Alexopoulos H; McMenamin M; Carvajal-González A; Alexander SK; Deacon R; Erdelyi F; Szabó G; Lang B; Blaes F; Brown P; Vincent A
JAMA Neurol; 2013 Sep; 70(9):1140-9. PubMed ID: 23877118
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.
Vale TC; Pedroso JL; Alquéres RA; Dutra LA; Barsottini OG
J Neurol Sci; 2015 Dec; 359(1-2):21-3. PubMed ID: 26671081
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy.
Liimatainen S; Peltola M; Sabater L; Fallah M; Kharazmi E; Haapala AM; Dastidar P; Knip M; Saiz A; Peltola J
Epilepsia; 2010 May; 51(5):760-7. PubMed ID: 19817821
[TBL] [Abstract][Full Text] [Related]
17. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies.
Dalakas MC; Li M; Fujii M; Jacobowitz DM
Neurology; 2001 Sep; 57(5):780-4. PubMed ID: 11552003
[TBL] [Abstract][Full Text] [Related]
18. [Autoantibodies to GAD and autoimmune-mediated neurological diseases].
Mitoma H; Mizusawa H
Nihon Rinsho; 2013 May; 71(5):921-6. PubMed ID: 23777105
[TBL] [Abstract][Full Text] [Related]
19. New autoantibody mediated disorders of the central nervous system.
Lang B; Dale RC; Vincent A
Curr Opin Neurol; 2003 Jun; 16(3):351-7. PubMed ID: 12858073
[TBL] [Abstract][Full Text] [Related]
20. Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67).
Guasp M; Solà-Valls N; Martínez-Hernández E; Gil MP; González C; Brieva L; Saiz A; Dalmau J; Graus F; Ariño H
J Neuroimmunol; 2016 Nov; 300():15-17. PubMed ID: 27806870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
